Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer

New England Journal of Medicine 2026

View at publisher
Authors: Eileen M. O’Reilly, Zev A. Wainberg, Andrew E. Hendifar, Mitesh J. Borad, Filippo Pietrantonio, Shubham Pant, Pascal Hammel, Chiara Cremolini, Gulam A. Manji, Paul E. Oberstein, Ignacio Garrido-Laguna, Christoph Springfeld
+8 more Nilofer S. Azad, Makoto Ueno, Stephen Y. Chui, Ying Zhang, Hina Patel, Yeonju Lee, Zeena Salman, Brian M. Wolpin
DOI: 10.1056/nejmoa2605555
Cited by: 81
References: 30

Abstract

BACKGROUND: mutations present in more than 90% of cases. Daraxonrasib is an oral RAS(ON) multiselective, tri-complex inhibitor of the active guanosine triphosphate-bound state of mutant and wild-type RAS. METHODS: G12 and overall populations. Safety was also assessed. RESULTS: G12 population was 7.3 months with daraxonrasib and 3.5 months with chemotherapy, and that in the overall population was 7.2 months and 3.6 months, respectively; the hazard ratios were 0.45 and 0.49, respectively (P

Fields of Study & Subjects

Pancreatic and Hepatic Oncology Research Lung Cancer Research Studies Neuroendocrine Tumor Research Advances

Publication details

Journal / source
New England Journal of Medicine
Publisher
Massachusetts Medical Society
Volume
395
Issue
4
Pages
325–337
Publication date
31 May 2026
Language
EN